

CITATION REPORT

List of articles citing

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

DOI: 10.1016/j.ijantimicag.2020.105938
International Journal of Antimicrobial Agents, 2020,
55, 105938.

Source: <https://exaly.com/paper-pdf/76932019/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
770	Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. 2020 , 11, 552909		136
769	Declaraci3n consenso de la Asociaci3n Colombiana de Medicina Cr3tica y Cuidados Intensivos (AMCI) para atenci3n y manejo del paciente pedi3trico con sospecha o confirmaci3n de infecci3n severa por SARS-CoV-2. 2020 , 20, 113-127		0
768	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. 2020 , 49, 763-773		13
767	COVID-19 infection and cardiac arrhythmias. 2020 , 30, 451-460		49
766	Severe COVID-19: what have we learned with the immunopathogenesis?. 2020 , 60, 50		29
765	Nanomedicine strategies to target coronavirus. 2020 , 35, 100961		28
764	Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. 2020 , 10,		8
763	Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study. 2020 , 9, 523-534		11
762	A comprehensive review about SARS-CoV-2. 2020 , 15, 625-648		37
761	Finding potent inhibitors for COVID-19 main protease (M): an approach using SARS-CoV-3CL protease inhibitors for combating CORONA. 2020 , 1-12		12
760	Current treatment of COVID-19 in renal patients: hope or hype?. 2020 , 15, 1389-1398		6
759	Hydroxy-chloroquine to treat COVID-19 - infected patients: Some lessons from medical anthropology and history of medicine. 2020 , 15, 100587		
758	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. 2020 , 75, 458-466		19
757	Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 Etketoamide derivative and Pentagastrin: An in-silico drug discovery approach. 2020 , 101, 107730		13
756	Credible Protein Targets and Curative Strategies for COVID-19: a Review. 2020 , 2, 1-10		3
755	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 1-24	5.5	11
754	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. 2020 , 13, 463-484		5

753	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
752	The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine. 2020 , 11, 1253	1
751	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. 2020 , 131, 110668	59
750	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020 , 32, 3159-3166	9
749	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. 2020 , 259, 118275	44
748	Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID-19. 2020 , 9, 6082-6092	3
747	Pharmaco-Immunomodulatory Therapy in COVID-19. 2020 , 80, 1267-1292	128
746	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. 2020 , 18, 2629-2635	53
745	Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. 2020 , 319, C500-C509	4
744	Immune-mediated approaches against COVID-19. 2020 , 15, 630-645	178
743	A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. 2020 , 11, 1736	26
742	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. 2020 , 18, 367-375	15
741	Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment. 2020 , 2, 210-216	14
740	Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections. 2020 , 39, 1687-1702	16
739	Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. 2020 , 57, 4106-4116	29
738	Ozone (O ₃) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage. 2020 , 2, 1-9	19
737	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. 2020 , 203, 112647	17
736	Targeting zinc metalloenzymes in coronavirus disease 2019. 2020 , 177, 4887-4898	17

735	Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. 2020 , 97, 872-881	6
734	The dynamic treatment of SARS-CoV-2 disease. 2020 , 33, 572-579	1
733	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. 2020 , 59, 337-345	17
732	Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. 2021 , 31, e2194	6
731	Impact of Gastrointestinal Symptoms in COVID-19: a Molecular Approach. 2020 , 2, 1-12	10
730	Molecular dynamics simulation perception study of the binding affinity performance for main protease of SARS-CoV-2. 2020 , 1-16	9
729	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. 2020 , 45, 1	24
728	Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019. 2021 , 10, 706-713	13
727	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. 2020 , 11, 1481-1495	6
726	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. 2020 , 9,	6
725	Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis. 2020 , 38, 265-272	3
724	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. 2020 , 7, 606393	17
723	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. 2020 , 10, 572329	3
722	The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. 2020 , 100, 67-74	7
721	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
720	Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. 2020 , 41, 856-859	15
719	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
718	Role for antimalarials in the management of COVID-19. 2020 , 32, 449-457	5

717	Rheumatology Drugs and COVID-19. 2020 , 20, 1-3		
716	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949		163
715	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	11
714	Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?. 2020 , 22, 864-865		2
713	Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study. 2021 , 39, 7322-7334		14
712	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. 2020 , 35, 725-733		20
711	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. 2020 , 884, 173381		9
710	Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke. 2020 , 29, 105182		14
709	A Review on Currently Available Potential Therapeutic Options for COVID-19. 2020 , 13, 443-467		11
708	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. 2020 , 38, 2209-2217		21
707	Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future. 2020 , 15, 471-482		8
706	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820		12
705	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159		22
704	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,		27
703	Drug Discovery Strategies for SARS-CoV-2. 2020 , 375, 127-138		51
702	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. 2020 , 7, 482		22
701	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106119	14.3	24
700	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. 2020 , 14, 3001-3013		15

699	Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?. 2020 , 99, 75-76		8
698	Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. 2020 , 56,		24
697	Is there really room for anti-rheumatic drugs in the treatment of COVID-19?. 2020 , 49, 412-413		0
696	Nicotine and the nicotinic cholinergic system in COVID-19. 2020 , 287, 3656-3663		28
695	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. 2020 , 25, 1822-1838		5
694	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,		4
693	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. <i>Annals of Medicine and Surgery</i> , 2020 , 57, 236-243	2	23
692	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240		4
691	Current Options in the Treatment of COVID-19: A Review. 2020 , 13, 1999-2010		5
690	Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020. 2020 , 6, 1-10		10
689	Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. 2020 , 63, 2-9		11
688	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). <i>Therapeutics and Clinical Risk Management</i> , 2020 , 16, 933-946	2.9	4
687	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264		5
686	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. 2020 , 2020, 8822753		3
685	QT interval measurement with portable device during COVID-19 outbreak. 2020 , 30, 100644		2
684	The Strengths of Scanning Electron Microscopy in Deciphering SARS-CoV-2 Infectious Cycle. 2020 , 11, 2014		24
683	COVID-19: an update on diagnostic and therapeutic approaches. 2020 , 53, 191-205		48
682	Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. 2020 , 40, 469-471		17

681	The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. 2020 , 39, 3223-3235	19
680	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
679	Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. 2020 , 19, 4706-4717	9
678	Therapeutic Effectiveness of Interferon- β Against COVID-19: The Cuban Experience. 2020 , 40, 438-442	27
677	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. 2020 , 82, 38-47	64
676	Lessons for teaching from the pandemic. 2020 ,	1
675	Epigenetic susceptibility to severe respiratory viral infections and its therapeutic implications: a narrative review. 2020 , 125, 1002-1017	20
674	Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?. 2020 , 11, 2014	25
673	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. 2020 , 6, 1-9	37
672	Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials. 2020 , 56, 606-608	8
671	What are the drugs having potential against COVID-19?. 2020 , 1-21	4
670	A model for the effective COVID-19 identification in uncertainty environment using primary symptoms and CT scans. 2020 , 26, 3088-3105	14
669	Neutrophil Extracellular Traps and By-Products Play a Key Role in COVID-19: Pathogenesis, Risk Factors, and Therapy. 2020 , 9,	47
668	Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. 2020 , 2, 5046-5089	16
667	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an repurposing study. 2020 , 12, 1815-1828	51
666	COVID-19 Pandemic: A Case for Phytomedicines. 2020 , 15, 1934578X20945086	14
665	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. 2020 , 57, 4856-4877	20
664	The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). 2020 , 35, 1-12	9

663	Layer-By-Layer Nanocoating of Antiviral Polysaccharides on Surfaces to Prevent Coronavirus Infections. 2020 , 25,	14
662	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. 2020 , 2, e698-e711	71
661	New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. 2020 , 21,	15
660	Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?. 2020 , 10,	91
659	Can plastic waste management be a novel solution in combating the novel Coronavirus (COVID-19)? A short research note. 2021 , 39, 910-913	4
658	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. 2020 , 25,	15
657	Identification of Persuasive Antiviral Natural Compounds for COVID-19 by Targeting Endoribonuclease NSP15: A Structural-Bioinformatics Approach. 2020 , 25,	8
656	Lethal Arrhythmia () in COVID-19: An Event Synergistically Induced by Viral Associated Cardiac Injury, Hyperinflammatory Response, and Treatment Drug?. 2020 , 13, 1179547620972397	3
655	Trials of treatments for COVID-19: Review of drugs are tested. 2020 , 1664, 012086	1
654	Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection. 2020 , 11, 569849	7
653	Compilation of antiviral treatments and strategies to fight fish viruses. 2020 , 13, 1223	4
652	Protein-ligand binding interactions of imidazolium salts with SARS CoV-2. 2020 , 6, e05544	3
651	Recent progress in the repurposing of drugs/molecules for the management of COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 889-897	5-5 9
650	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. 2020 , 10, 19199	7
649	Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. 2020 , 10, 19125	28
648	Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic. 2020 , 21, 922-923	2
647	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. <i>Microorganisms</i> , 2020 , 8,	4-9 26
646	Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M.. 2020 , 10, 40264-40275	13

645	Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAI0a Living Working Document. 2020 , 13, e007175		27
644	Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. 2020 , 10, 5932-5942		76
643	Malaria prophylaxis approach during COVID-19 pandemic. 2020 , 38, 101716		2
642	COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?. 2020 , 216, A1-A2		13
641	COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation. 2020 , 12,		225
640	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. 2020 , 382, 2411-2418		1063
639	A global treatments for coronaviruses including COVID-19. 2020 , 235, 9133-9142		56
638	COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. 2020 , 141, 111418		83
637	Covid-19 and drug therapy, what we learned. 2020 , 42, 833-836		7
636	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 106007	14.3	18
635	Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106012	14.3	131
634	ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. 2020 , 53, 425-435		264
633	The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review. 2020 , 129, 104806		117
632	Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. 2020 , 71, 2265-2268		6
631	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. 2020 , 12,		48
630	Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. 2020 ,		14
629	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. 2020 , 53, 43-52		58
628	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. 2020 , 142, 109783		29

627	Drug repurposing against COVID-19: focus on anticancer agents. 2020 , 39, 86	44
626	Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A "Living Working Document". 2020 , 66, 588-598	29
625	Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. 2020 , 43, 341-354	50
624	SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges. 2020 , 10, 3641	20
623	(Iso)Quinoline-Artemisinin Hybrids Prepared through Click Chemistry: Highly Potent Agents against Viruses. 2020 , 26, 12019-12026	10
622	The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246	12
621	Current Perspective of Antiviral Strategies against COVID-19. 2020 , 6, 1624-1634	31
620	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. 2020 , 11, 245-268	69
619	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. 2020 , 158, 104899	118
618	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. 2020 , 158, 104904	72
617	Targeting Nephrylsin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. 2020 , 178, 114057	22
616	Potential specific therapies in COVID-19. 2020 , 14, 1753466620926853	13
615	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). 2020 , 40, 591-601	55
614	COVID-19: Structural predictions of viral success. 2020 , 74, e13568	
613	Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. 2020 , 8, 252	26
612	Fight against novel coronavirus: A perspective of medicinal chemists. 2020 , 201, 112559	44
611	Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. 2020 , 22, 86	15
610	Focus on the 2019 novel coronavirus (SARS-CoV-2). 2020 , 15, 905-918	18

609	COVID-19 and hydroxychloroquine: Is the wonder drug failing?. 2020 , 78, 1-3		7
608	Tackling SARS-CoV-2: proposed targets and repurposed drugs. 2020 , 12, 1579-1601		32
607	Deploying Biomolecules as Anti-COVID-19 Agents. 2020 , 60, 263-268		31
606	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. 2020 , 43, 699-709		31
605	Cardiac effects and toxicity of chloroquine: a short update. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106057	14.3	23
604	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070		75
603	Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?. 2020 , 214, 107618		120
602	Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. 2021 , 39, 4949-4961		19
601	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. 2020 , 19, 100		45
600	Risk of using hydroxychloroquine as a treatment of COVID-19. 2020 , 31, 111-116		17
599	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?. 2020 , 39, 2461-2465		19
598	Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials. 2020 , 56, 606-608		8
597	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. 2020 , 155, 23-25		0
596	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. 2020 , 100, 1455-1466		75
595	Investigation of Some Antiviral -Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations. 2020 , 21,		78
594	Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment?. 2020 , 15, 54		22
593	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829		3
592	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106054	14.3	168

591	Effet clinique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d'une étude observationnelle. 2020 , 55, 398-403	2
590	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. 2020 , 108, 17-41	354
589	Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?. 2020 , 10, 171-186	58
588	Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19. 2020 , 144, 109802	3
587	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. 2020 , 19, 102523	241
586	Teicoplanin: an alternative drug for the treatment of COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105944	14.3 161
585	COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?. 2020 , 213, A3-A4	27
584	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. 2020 , 33, 824-825	96
583	Drug targets for COVID-19 therapeutics: Ongoing global efforts. 2020 , 45, 1	54
582	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. 2020 , 10, 277-287	37
581	Potentials of plant-based substance to inhibit and probable cure for the COVID-19. 2020 , 44, 228-241	38
580	The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery. 2020 , 25, 41-46	4
579	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59
578	Potential benefits of combination of and Zn supplements to treat COVID-19. 2020 , 23, 100382	27
577	Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. 2020 , 73, 109706	13
576	Pandemic COVID-19: Current status and challenges of antiviral therapies. 2020 , 7, 502-519	7
575	Is hydroxychloroquine beneficial for COVID-19 patients?. 2020 , 11, 512	57
574	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 1119-1133	5.5 16

573	Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. 2020 , 21,		50
572	Chloroquine: A Potential Drug in the COVID-19 Scenario. 2020 , 5, 399-410		7
571	Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism. 2020 , 260, 127558		37
570	Coronavirus Disease 2019-COVID-19. 2020 , 33,		386
569	Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19. 2020 , 14, 100547		2
568	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. 2020 , 286, 198073		25
567	Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. 2020 , 36, 101615		54
566	SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction. 2020 , 21,		48
565	Association of Comorbidities with Coronavirus Disease 2019: A Review. 2020 , 56, 102-111		3
564	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106078	14.3	29
563	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. 2020 , 10,		76
562	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2020 , 26, 880-894		23
561	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. 2020 , 52, 54-72		59
560	SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. 2020 , 27, 4536-4541		164
559	Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. 2020 , 37, 2575-2579		22
558	Antibody therapies for the treatment of COVID-19. 2020 , 3, 101-108		7
557	COVID-19 in kidney transplant recipients. 2020 , 20, 1819-1825		145
556	COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?. 2020 , 86, 1176-1177		11

555	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. 2020 , 9,	112
554	What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. 2020 , 6, 1-4	23
553	Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. 2020 , 20, 117-120	52
552	COVID-19: A review of therapeutics under investigation. 2020 , 1, 231	20
551	Chloroquine for COVID-19 Infection. 2020 , 43, 393-394	27
550	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. 2020 , 252, 117652	206
549	Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. 2020 , 35, 101653	57
548	The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?. 2020 , 2, 296-303	33
547	The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity. 2020 , 7, 176	0
546	Chloroquine and its derivatives in the management of COVID-19: A scoping review. 2020 , 40, 80-95	4
545	. 2020 , 87, 143-145	
544	Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. 2020 , 18, 1320-1323	103
543	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. 2020 , 155, 23-25	3
542	Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. 2020 , 189, 635-639	26
541	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. 2020 , 19, 16	24
540	In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. 2020 , 145, 104228	171
539	Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?. 2020 , 140, 109756	9
538	Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105982	14.3 160

537	CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. 2020 , 16, 434-440	256
536	Influence of media composition on recombinant monoclonal IgA1 glycosylation analysed by lectin-based protein microarray and MALDI-MS. 2020 , 314-315, 34-40	7
535	Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. 2020 , 87, 187-189	13
534	Current epidemiological and clinical features of COVID-19; a global perspective from China. 2020 , 81, 1-9	162
533	COVID-19 and psoriasis: Should we fear for patients treated with biologics?. 2020 , 33, e13434	30
532	Does hydroxychloroquine combat COVID-19? A timeline of evidence. 2020 , 83, e33-e34	21
531	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. 2021 , 17, 483-486	40
530	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. 2021 , 17, 1954-1963	80
529	Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19. 2021 , 28, 54	0
528	Can Zn Be a Critical Element in COVID-19 Treatment?. 2021 , 199, 550-558	66
527	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. 2021 , 56, 3-11	11
526	Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. 2021 , 37, e3379	10
525	SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases. 2021 , 23, e13394	6
524	Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. 2021 , 890, 173720	8
523	Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. 2021 , 224, 121862	23
522	Antivirals for COVID-19: A critical review. 2021 , 9, 90-98	79
521	COVID-19 in solid organ transplant recipients. 2021 , 23, e13419	3
520	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121	8

519	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14
518	Perspectives on mechanistic implications of ROS inducers for targeting viral infections. 2021 , 890, 173621	5
517	Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. 2021 , 1228, 129459	5
516	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. 2021 , 135, 170428	5
515	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. 2021 , 183, 114296	44
514	Repurposing medications. 2021 , 19, 336-340	4
513	In vitro cultivation of tansy (<i>Tanacetum vulgare</i> L.): a tool for the production of potent pharmaceutical agents. 2021 , 258, 587-599	7
512	Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106247	14.3 4
511	Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. 2021 , 1162, 122469	1
510	Transition metal complexes as potential tools against SARS-CoV-2: an in silico approach. 2021 , 45, 1924-1933	14
509	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14
508	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. 2021 , 90, 107228	12
507	Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites. 2021 , 31, 101890	23
506	FSS-2019-nCov: A deep learning architecture for semi-supervised few-shot segmentation of COVID-19 infection. 2021 , 212, 106647	44
505	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. 2021 , 7, 1389-1408	39
504	The H-ATPase (V-ATPase): from proton pump to signaling complex in health and disease. 2021 , 320, C392-C414	21
503	HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers. 2021 , 73, 74-76	0
502	SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19. 2021 , 226, 152021	17

501	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. 2021 , 134, 166-175	7
500	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. 2021 , 87, 2170-2185	7
499	Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M and spike protein: Drug repurposing approach. 2021 , 82, 217-229	6
498	Combating COVID-19: The role of drug repurposing and medicinal plants. 2021 , 14, 495-503	16
497	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. 2021 , 41, 72-135	15
496	Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. 2021 , 52, 15-24	50
495	COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. 2021 , 17, 113-131	8
494	Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. 2021 , 38, 480-488	
493	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
492	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. 2021 , 25, 13-22	5
491	COVID-19-Directed Medications. 2021 , 171-179	
490	Host-directed Therapy: A New Arsenal to Come. 2021 , 24, 59-70	0
489	Índice neutrófilos/linfocitos: un predictor de mortalidad en paciente con infección por SARS-CoV-2. 2021 , 35, 130-135	0
488	New Insights Into Drug Repurposing for COVID-19 Using Deep Learning. 2021 , 32, 4770-4780	1
487	Therapeutic options for COVID-19: a quick review. 2021 , 33, 67-84	4
486	Potential Therapeutic Approaches for SARS CoV2 Infection. 2021 , 71-114	
485	Therapeutic and Diagnostic Approaches for SARS-CoV-2. 2021 , 07, 63-79	0
484	Drug Combinations. 2021 ,	

483	Application of machine learning for the diagnosis of COVID-19. 2021 , 175-194	10
482	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. 2021 , 25, 441-452	2
481	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri. 00,	0
480	Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2. 2020 , 15, 3433-3445	15
479	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52
478	Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia. 2021 , 43, 342-348	6
477	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89	
476	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. 2021 , 32, 3-17	3
475	Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. 2021 , 105, 1333-1343	29
474	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. 2021 , 10, 2126-2139	1
473	Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak. 2021 , 45, 27	21
472	A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection. 2021 , 26, 100714	1
471	Repurposing New Use for Old Drug Chloroquine against Metabolic Syndrome: A Review on Animal and Human Evidence. 2021 , 18, 2673-2688	4
470	COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?. 2021 , 19, 1371-1378	13
469	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. 2021 , 23, 14	93
468	COVID-19, prevention and treatment with herbal medicine in the herbal markets of Salé Prefecture, North-Western Morocco. 2021 , 42, 101285	18
467	Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M) of SARS-CoV-2. 2021 , 27, 97	6
466	Can ACE2 Receptor Polymorphism Predict Species Susceptibility to SARS-CoV-2?. 2020 , 8, 608765	16

465	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. 2021 , 25, 1905-1927	8
464	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. 2021 ,	19
463	Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review. 2020 , 11, 585331	5
462	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. 2021 , 22, 62-66	2
461	Expression of ACE2 receptor, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin (1-7), is modulated in COVID-19 patients.	1
460	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. 2021 , 54, 37-45	2
459	Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. 2021 , 13,	40
458	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. 2021 , 2021, 8821318	4
457	Interactoma de predisposici3n y resistencia a SARS-CoV-2. Prote3nas, genes y funciones.. 2021 , 6, 1555-1562	
456	Molecular Elucidation and Therapeutic Targeting for combating COVID19: Current Scenario and Future Prospective. 2021 ,	
455	Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review. 2021 , 133, 548-551	3
454	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7
453	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. 2021 ,	0
452	Recent Developments of Quinoline Derivatives and their Potential Biological Activities. 2021 , 18, 248-269	3
451	Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. 2021 , 9, 436	4
450	Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?. 2021 , 24, 587-590	2
449	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. 2021 , 27, 281-290	8
448	A novel Covid-19 and pneumonia classification method based on F-transform. 2021 , 210, 104256	21

447	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
446	Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research. 2020 , 11, 578970	38
445	Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties. 2021 , 7, e06603	7
444	The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis.	
443	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. 2021 , 36, S253-S263	24
442	Ophthalmological aspects of coronavirus infections. 2021 , 14, 7-14	4
441	Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study. 2021 , 32, 1-10	3
440	Determination of Potential Drug Candidate Molecules of the for COVID-19 Treatment. 2021 , 7, 1-7	4
439	A mini review on the pathogenesis, diagnosis and treatment options for COVID-19. 2021 ,	
438	A Review of the Progress of COVID-19 Vaccine Development.	1
437	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. 2021 , 104, 7-14	9
436	Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis. 2020 , 9, 1316	10
435	Docking and Molecular Dynamic Simulations Study to Search Curcumin Analogue Compounds as Potential Inhibitor Against SARS-CoV-2: A Computational Approach. 2021 , 24, 85-90	1
434	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). 2021 , 45, 104-121	1
433	An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome-Coronavirus. 2021 , 8, 637550	4
432	Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. 2021 , 15, 1213-1223	0
431	Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design. 2021 , 130, 104222	6
430	Chloroquine-induced Prolonged QT Interval in COVID-19 Patients in Indonesia: Case Series. 2021 , 14, 01-05	0

429	Plant Culture Technologies; A Promise Into Factories of Secondary Metabolites Against COVID-19. 2021 , 12, 610194	8
428	The find of COVID-19 vaccine: Challenges and opportunities. 2021 , 14, 389-416	18
427	Development of an easy and rapid analytical method for the extraction and preconcentration of chloroquine phosphate from human biofluids prior to GC-MS analysis. 2021 , 108, 106949	5
426	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. 2021 , 14, 331-346	6
425	A REVIEW ON EMERGING PATHOGENESIS OF COVID-19 AND POINTS OF CONCERN FOR RESEARCH COMMUNITIES IN NIGERIA. 2021 , 15, 36-43	0
424	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. 2021 , 246, 1533-1540	1
423	Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight. 2021 , 22, 192-199	2
422	Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV).	2
421	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677	28
420	PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. 2021 , 185, 114431	20
419	A therapeutic journey of potential drugs against COVID-19. 2021 ,	
418	Chloroquine Analogs: An Overview of Natural and Synthetic Quinolines as Broad Spectrum Antiviral Agents. 2021 , 27, 1185-1193	2
417	The role of nanotechnology in current COVID-19 outbreak. 2021 , 7, e06841	16
416	Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus. 2021 , 12, 580147	1
415	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. 2021 , 12, 576093	10
414	A Systematic Review on Various Therapeutic Options for Coronavirus Outbreak. 2021 , 11, 185-194	
413	SARS-CoV-2 Therapy: Old Drugs as New Interventions. 2021 , 2, 142-150	1
412	Novel Coronavirus in India and Outbreaks Around World: A Statistical Analysis of Odisha, India and the World. 2021 , 2, 369-383	0

411	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021,	
410	The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?. 2021, 153, 104799	47
409	Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection. 2021, 12,	3
408	COVID-19: An Insight on the Third Respiratory Global Emergency of the Century. 2021, 2, 339-345	
407	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. 2021, 37, 929-938	4
406	Role of phytoconstituents in the management of COVID-19. 2021, 341, 109449	9
405	Coronavirus Disease 2019: An Overview of the Complications and Management. 1-28	
404	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. 2021, 53, 137-143	2
403	The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy. 2021, 22,	8
402	The understanding of the immunopathology in COVID-19 infection. 2021, 81, 255-263	1
401	A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019. 2021, 2,	
400	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. 2021, 8,	
399	The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection. 2021, 17, 141-152	1
398	Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. 2021, 35, e22795	1
397	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. 2021, 21, 1123-1143	3
396	An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19). 2021, 103, 107155	30
395	Essentials in the Treatment of COVID-19. 2021, 19,	
394	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. 2021, 13,	12

- 393 Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. **2021**, 137, 111330 13
- 392 Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. **2021**, 28, 2887-29425
- 391 Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. **2021**, 1 1
- 390 SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. **2021**, 137, 111352 14
- 389 SARS-CoV-2-Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. **2021**, 10, 4
- 388 Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19. **2021**, 12, 652335 8
- 387 Current Overviews on COVID-19 Management Strategies. **2021**, 3
- 386 Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. **2021**, 154, 104831 32
- 385 Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19. **2021**, 21, 1004-1016 2
- 384 Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. **2021**, 151, 112106 3
- 383 Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. **2021**, 19, 68 2
- 382 An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia. **2021**, 16, e0252302 7
- 381 Anti-Cancer Potential of Some Commonly Used Drugs. **2021**, 27, 4530-4538 2
- 380 Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. **2021**, 13, 184-202 1
- 379 A Multidisciplinary Approach to Coronavirus Disease (COVID-19). **2021**, 26, 3
- 378 Chloroquine as Chemoprophylaxis for COVID-19: Will This Work. **2021**, 21, 473-474 9
- 377 COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. **2021**, 58, 4188-4215 5
- 376 Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review. **2021**, 2, 521-526

375	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. 2021 , 10, 100085	5
374	Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. 2021 , 138, 111518	25
373	Potent phytochemicals against COVID-19 infection from phyto-materials used as antivirals in complementary medicines: a review. 2021 , 7, 113	3
372	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. 2021 , 16, e0251731	5
371	A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. 2021 , 181, 605-611	9
370	Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin. 2021 , 12, 556550	4
369	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. 2021 , 10,	2
368	Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy. 2021 , 2, 422-430	
367	Mechanism of Action of Chloroquine/Hydroxychloroquine for Covid-19 Infection. 2021 , 2,	2
366	Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. 2021 , 12, 625732	22
365	An update on emerging therapeutics to combat COVID-19. 2021 , 129, 104-129	5
364	A review on recent electroanalytical methods for the analysis of COVID-19 drugs.	0
363	Statins in COVID-19 Therapy. 2021 , 11,	2
362	Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. 2021 , 28, 3803-3824	7
361	Syntheses, crystal structures, antioxidant, in silico DNA and SARS-CoV-2 interaction studies of triorganotin(IV) carboxylates. 2021 , 1234, 130190	3
360	COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach. 2021 , 15, 3313-3330	2
359	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. 2021 , 139, 111642	19
358	Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics. 2021 , 16, 4959-4984	5

- 357 A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. **2021**, 152, 110619 0
- 356 Prophylactic and therapeutic potential of selected immunomodulatory agents from Ayurveda against coronaviruses amidst the current formidable scenario: an analysis. **2021**, 1-53 2
- 355 Clinical Features of HIV Arthropathy in Children: A Case Series and Literature Review. **2021**, 12, 677984
- 354 Theranostic Approach for Coronavirus. **2021**, 261-274
- 353 Pathogenesis of Coronaviruses Through Human Monocytes and Tissue Macrophages. **2021**, 34, 597-606 2
- 352 SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions. **2021**, 2, 0
- 351 8-hydroxyquinoline-5-(N-4-chlorophenyl) sulfonamide and fluconazole combination as a preventive strategy for biofilm in haemodialysis devices. **2021**, 70, 1
- 350 A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. **2021**, 1-12 2
- 349 ORF3a-Mediated Incomplete Autophagy Facilitates Severe Acute Respiratory Syndrome Coronavirus-2 Replication. **2021**, 9, 716208 19
- 348 Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. **2021**, 1 3
- 347 Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. **2021**, 18, e1003682 29
- 346 An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. **2021**, 45, 123 1
- 345 Mechanisms of action and adverse effects of the major therapeutic agents in trial for COVID-19 therapeutics: Review of literature. **2021**, 2,
- 344 Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment. **2021**, 15, 606-615 2
- 343 Severe Acute Respiratory Coronavirus-2: A Critical Review of Virus Biology, Genome and Pathophysiology. **2021**, 15, 286-295
- 342 Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19. **2021**, 4, 2
- 341 Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19. **2021**, 22, 214 2
- 340 Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development.

339	Binding of Chloroquine to Whey Protein Relieves Its Cytotoxicity while Enhancing Its Uptake by Cells. 2021 , 69, 10669-10677	1
338	Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools. 2021 , 781, 146400	5
337	Therapeutic efficacy of macrolides in management of patients with mild COVID-19. 2021 , 11, 16361	5
336	The Challenges and Successes of Dealing with the COVID-19 Pandemic in India. 2021 , 12, 205-218	0
335	Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS-CoV-2. 2021 , 1-15	1
334	A fuzzy logic-based computational method for the repurposing of drugs against COVID-19. 2021 ,	0
333	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. 2021 , 9, 3237-3248	1
332	Natural Products as Potential Lead Compounds for Drug Discovery Against SARS-CoV-2. 2021 , 11, 611-628	2
331	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. 2021 , 43, 102135	4
330	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. 2021 , 1-27	3
329	Cytokine Storm and Immunomodulation in COVID-19: a Review. 2021 , 02,	
328	Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and COVID-19 drug candidate molecules. 2021 , 29, 53-53	1
327	Keeping Meta-Analyses Hygienic During the COVID-19 Pandemic. 2021 , 9, 722458	0
326	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. 2021 , 231, 108804	4
325	Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2). 2021 , 192, 114724	2
324	The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study. <i>Annals of Medicine and Surgery</i> , 2021 , 70, 102867	2 1
323	From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. 2021 , 201, 111555	1
322	COVID-19, cytokines, inflammation, and spices: How are they related?. 2021 , 284, 119201	15

321	Therapeutic Strategies for Treatment of COVID-19. 2022 , 55-72	
320	Computational Modeling of Chloroquine Analogues for Development of Drugs Against Novel Coronavirus (nCoV). 2021 , 579	
319	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. 2021 , 16, 281-308	21
318	Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc. 2021 , 199, 4101-4108	17
317	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. 2021 , 6,	22
316	COVID-19 Antiviral and Treatment Candidates: Current Status. 2021 , 21, e7	5
315	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 2021 , 21, 5	4
314	Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?. 2021 , 13, 4-10	0
313	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. 2021 , 2, 1	6
312	Advancements in research and development to combat COVID-19 using nanotechnology. 2021 , 6, 1	26
311	The journey of antimalarial drugs against SARS-CoV-2: Review article. 2021 , 24, 100604	17
310	Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. 2020 , 60, 815-825	40
309	Therapeutic approaches against coronaviruses acute respiratory syndrome. 2021 , 9, e00691	4
308	COVID-19: Hard Road to Find Integrated Computational Drug and Repurposing Pipeline. 2021 , 295-309	4
307	The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?. 2020 , 27, 863-869	125
306	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. 2020 , 53, 100721	44
305	A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106028	14.3 62
304	Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. 2020 , 13, 865-867	6

303	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. 2020 , 28, 1333-1352		11
302	RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. 2020 ,		464
301	SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. 2020 , 134, 1295-1300		22
300	Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. 2021 , 39, 3760-3770		69
299	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 1009-1027	5-5	17
298	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184		41
297	SARS-CoV-2 infection and the antiviral innate immune response. 2020 , 12, 963-967		12
296	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. 2020 , 99, e23720		14
295	Current drugs with potential for coronavirus disease 2019 therapy. 2020 , Publish Ahead of Print,		2
294	Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review.		14
293	Chloroquine and hydroxychloroquine for the treatment of COVID-19: A living systematic review protocol.		3
292	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study.		37
291	Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.		1
290	Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.		6
289	Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and PBPK model.		1
288	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study.		21
287	Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea.		7
286	Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis.		5

285	The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators. 2020,	34
284	Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports.	2
283	Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience.	9
282	Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza.	10
281	Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro.	2
280	MMGB/SA Consensus Estimate of the Binding Free Energy Between the Novel Coronavirus Spike Protein to the Human ACE2 Receptor. 2020,	4
279	ORF3a mediated-incomplete autophagy facilitates SARS-CoV-2 replication.	6
278	Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. 2020, 2020, 8827752	6
277	Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. 2020, 35, 83	6
276	An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management. 2020, 61, 392-394	1
275	Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. 2020, 5,	145
274	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. 2020, 22, 290	17
273	Battling COVID-19: using old weapons for a new enemy. 2020, 6, 6	12
272	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. 2020, 9,	9
271	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. 2020, 9, 514	7
270	Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis. 2020, 9, 1316	12
269	Novel respiratory infectious diseases in Korea. 2020, 37, 286-295	1
268	Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients. 2020, 15, e0243598	1

267	CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST'S THOUGHTS. 2020 , 58, 123-132	27
266	COVID-19: the new challenge for rheumatologists. 2020 , 14, 110-116	1
265	Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy. 2020 , 48, 1001-1007	1
264	Sustainable Post Covid19 Lockdown Strategy Through Evidence-Based Policy. 7,	5
263	SCIENTIST'S PURSUIT FOR CORONAVIRUS SARS-COV-2, WHICH CAUSES COVID-19: SCIENTIFIC STRATEGIES AGAINST PANDEMIC. 2020 , 29-71	3
262	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. 2020 , 27, e14-e25	4
261	Some opportunities for immunotherapy in coronavirus infection. 2020 , 10, 446-458	9
260	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. 2020 , 115, e200254	11
259	MENTAL ILLNESS IN THE GENERAL POPULATION AND HEALTH PROFESSIONALS DURING COVID-19: A SCOPING REVIEW. 29,	14
258	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. 2020 , 20,	8
257	COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?. 2020 , 251, 175-181	41
256	Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020. 2020 , 19, 992-1016	14
255	[The Agreed Experts' Position of the Eurasian Association of Therapists on Some new Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and Blood gas Exchange]. 2020 , 60, 9-19	16
254	Chitosan-drug encapsulation as a potential candidate for COVID-19 drug delivery systems: A review. 2020 , 7, 851-864	4
253	Need for Abundant Caution in Prophylactic Application of Chloroquine and Hydroxychloroquine for Viral Infections Including COVID-19: Possibility of Increased Susceptibility.	1
252	Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion.	11
251	An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease. 2020 , 12, 203-212	2
250	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. 2020 , 26, 4467-4485	17

249	Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. 2020 , 21, 1703-1721	5
248	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. 2020 , 20, 2210-2220	11
247	Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. 2020 , 22, e21758	13
246	Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-CoV-2 inhibitors. 2020 , 15, 267-275	21
245	Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19). 2020 , 14, 979-988	1
244	Iron overload and Hcpidin overexpression could play a key role in COVID infection, and may explain vulnerability in elderly, diabetics, and obese patients. 2020 , 91, e2020013	11
243	The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury. 2020 , 91, e2020142	1
242	Evaluation of Prognostic/Diagnostic Value of Hematological Markers in the Detection of Inflammation in Coronavirus Disease: A Review Study. 2020 , 28, 171-174	2
241	When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?. 2020 , 31, 94-97	6
240	A Computational Approach to Explore the Interaction of Semisynthetic Nitrogenous Heterocyclic Compounds with the SARS-CoV-2 Main Protease. 2020 , 11,	4
239	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. 2020 , 4,	61
238	COVID-19 FARMAKOTERAPİSİ 2020 , 11, 80-114	1
237	Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). 2020 , 46, 467-488	86
236	The Evolving COVID-19 Pandemic: An Update. 2020 , 49, e201-e203	0
235	Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19). 2020 , 10, 135-162	4
234	COVID-19 pandemic from an ophthalmology point of view. 2020 , 151, 411-418	16
233	Tele-consultations in the wake of COVID-19 - Suggested guidelines for clinical ophthalmology. 2020 , 68, 1316-1327	16
232	Severe acute respiratory syndrome-coronavirus 2 and novel coronavirus disease 2019: An extraordinary pandemic. 2020 , 37, 268-271	5

231	Wide Applications of Chloroquine Other Than Antimalarial. 2020 , 11, 251-281		1
230	Guide for Nuclear Medicine Applications During the COVID-19 Outbreak. 2020 , 29, 49-58		7
229	The COVID-19 Pandemic: Clinical Information for Ophthalmologists. 2020 , 50, 59-63		14
228	Current Approaches to COVID-19: Therapy and Prevention. 2020 , 24, 838-846		10
227	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. 2020 , 24, 1106-1113		1
226	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. 2020 , 11,		6
225	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. 2020 , 7, S110-S116		4
224	COVID-19 compared to other epidemic coronavirus diseases and the flu. 2020 , 10, 1-13		4
223	Current status of COVID-19 treatment: An opinion review. 2020 , 9, 27-37		4
222	Is Coronavirus Disease 2019 (COVID-19) Associated with Renal Involvement? A Review of Century Infection. 2020 , 13,		5
221	The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19. 2020 , 75, e2181		1
220	Chloroquine and hydroxychloroquine in the context of COVID-19. 2020 , 9,		23
219	Therapeutic Options for COVID-19: A Review. <i>Cureus</i> , 2020 , 12, e10480	1.2	13
218	Perspective from Ecuador, the Second Country with More Confirmed Cases of Coronavirus Disease 2019 in South America: A Review. <i>Cureus</i> , 2020 , 12, e7452	1.2	12
217	Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment. <i>Cureus</i> , 2020 , 12, e8268	1.2	2
216	Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. <i>Cureus</i> , 2020 , 12, e8342	1.2	24
215	Natural Potential Inhibitors for Covid 19 – An Insilico Approach. 2021 , 4913-4919		
214	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. 2021 , 22,		1

213	COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience. 2021 , 2021, 3129411	3
212	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. 2021 ,	1
211	One step derivatization and dispersive liquid-liquid microextraction of hydroxychloroquine sulfate for its sensitive and accurate determination using GC-MS. 2021 , 107130	1
210	Current treatment strategies for COVID-19 (Review). 2021 , 24,	2
209	Therapeutic strategies for Covid-19 based on molecular docking and dynamic studies to the ACE-2 receptors, Furin, and viral spike proteins. 2021 , 1-19	7
208	Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure. 2021 , 134, 2776-2787	3
207	Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. 2021 , 912, 174569	3
206	COVID-19. 2017 ,	
205	The Chemical Sciences' Advances on Coronavirus Disease 2019 (COVID-19). 2020 , 5, 179-184	
204	New Post-COVID-19 Biosafety Protocols in Pediatric Dentistry. 2020 , 20,	5
203	Rheumatoid Arthritis in the Era of COVID-19 Pandemic. 2020 , 31, 257-258	0
202	Ḃsan-COVID-19'da Pandemik SARS Coronavirus-2 Enfeksiyonlaṙ2020, 77-93	1
201	Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic. 2020 , 6, 006-008	
200	I. Cloroquina / hidroxicloroquina y azitromicina. Revisi̇n narrativa de seguridad. 2020 , 2, 71-82	
199	Chloroquine Administration in Breastfeeding Mothers Associates with Increased HIV-1 Plasma Viral Loads.	
198	First COVID-19 sub-intensive respiratory unit in Europe: the Italian experience. 2020 , 15, 682	1
197	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.	1
196	COVID-19 Disease Pandemic in the 21st Century: As Africa Braces up for the Disease What Needs to be known. 2020 , 1, 25-34	

- 195 Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19. **2020**, 50, 76-96 1
- 194 As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. **2020**, 1, 1-18
- 193 Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations. **2020**, 12, 721-730 1
- 192 [TRIBULACIONES DE LA INVESTIGACI3N EN TIEMPOS DE COVID-19]. **2020**, 71, 231-236
- 191 SARS-CoV-2: una nueva amenaza. **2020**,
- 190 Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera. **2020**, 134, 2235-2241 0
- 189 Two-Stage Deep Learning Framework for Discrimination between COVID-19 and Community-Acquired Pneumonia from Chest CT scans. **2021**, 152, 311-319 3
- 188 AMP functionalized curdlan nanoparticles as a siRNA carrier: Synthesis, characterization and targeted delivery via adenosine A receptor. **2021**, 193, 866-873 0
- 187 COVID-19 Drug Repositioning: Present Status and Prospects. **2022**, 645-671 0
- 186 Potenciales efectos proarr3micos de la farmacoterapia contra SARS-CoV-2. **2020**, 31, 199-204
- 185 Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Hydroxychloroquine in Healthy Volunteers. 2
- 184 COVID-19 Treatment at a Glance. **2020**, 21, 438-445 1
- 183 Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment. **2020**,
- 182 nCOVID-19: Its diagnosis, possible preventive measures, therapeutic interventions and management. **2020**, 115-129
- 181 Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician. **2020**, 33, 572-581
- 180 COVID-19 en ortopedia. **2020**, 34, 153-157
- 179 Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. **2020**, 20, 4-9 1
- 178 C3mo estimar la letalidad del COVID-19. **2020**, 67, 4-8 1

- 177 Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. **2020**, 11, 85-104
- 176 Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. **2020**, 123, 74
- 175 Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. **2020**, 61, 321-334 1
- 174 Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. **2020**, 24, S244-S253 0
- 173 OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. **2020**, 10, 9-20 0
- 172 COVID-19ân Tanve Tedavi Secinde Hematolojik Parametreler. 0
- 171 COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends. **2021**, 101, 108328 2
- 170 Clinical features and mechanistic insights into drug repurposing for combating COVID-19. **2021**, 142, 106114 6
- 169 Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis. 1
- 168 COVID-19âDA SOK SALINIM SENDROMU VE TEDAVYAKLAMLARI. 55-59
- 167 FMACOS ANTIMICROBIANOS E ANTIVIRAIS COM POTENCIAL USO TERAPTICO PARA A COVID-19. **2020**, 32, 109-119
- 166 How to manage rheumatic patients during the coronavirus pandemic. **2020**, 62, 176-177 1
- 165 What ophthalmologists need to know about pandemic of Corona Virus 19. **2020**, 050-053
- 164 COVID-19 and Rheumatology: so far, so close. **2020**, 135-143 0
- 163 TAMERON (SODIUM AMINODIGYROPTHALAZINEDIONE) AS A POTENTIAL COMPLEX DRUG FOR THE TREATMENT OF CORONAVIRUS INFECTION COVID-19. **2020**, 6, 67-75
- 162 Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. **2020**, 53-59
- 161 Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel. **2020**, 81-86
- 160 Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.

159	Hydroxychloroquine and the risk of respiratory infections among RA patients. 2020 , 6,	1
158	Binding Free Energy of the Novel Coronavirus Spike Protein and the Human ACE2 Receptor. 2020 ,	0
157	SARS-CoV-2: a new threat. 2020 ,	
156	In Silico Drug Repurposing of Penicillins to Target Main Protease Mpro of SARS-CoV-2. 2020 , 26, S52-S62	1
155	Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors. 2020 , 26, S63-S77	2
154	A Summary of Coronavirus Disease 2019: What We Should Know?. 2020 , 26, S24-S35	
153	Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. 2020 , 2, 100224	0
152	Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. 2020 , 21, 534-540	2
151	Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy.	
150	Treatments for COVID-19: emerging drugs against the coronavirus. 2020 , 91, 118-136	7
149	Management of Pemphigus in COVID-19 Pandemic Era; a Review Article. 2020 , 8, e51	9
148	Hydroxychloroquine in Dermatology and Beyond: Recent Update. 2020 , 11, 453-464	5
147	COVID 19: A Clinical Primer-Overview and Plaquenil/Zithromax. 2020 , 19, 12-14	
146	Treatment and prognosis of COVID-19: Current scenario and prospects (Review). 2021 , 21, 3	3
145	Investigating the factors affecting the survival rate in patients with COVID-19: A retrospective cohort study. 2020 , 34, 88	3
144	Is there a place for anti-inflammatory therapy in COVID-19?. 2020 , 12, 7076-7080	
143	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107	9
142	Tackling COVID-19 Using Small-Molecule Drugs. 2022 , 73-84	

141 Treatment and therapeutic agents. **2022**, 121-176

140 Introduction to COVID-19. **2022**, 3-16

139 Systematic Review of Sensorineural Hearing Loss Associated With COVID-19 Infection.. *Cureus*, **2021**, 13, e19757

1.2 2

138 Computational identification of potential inhibitory compounds in Indian medicinal and aromatic plant species against major pathogenicity determinants of SARS-CoV-2. **2021**, 1-19

2

137 Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. **2021**, 9,

9

136 Newly identified COVID-19 drug candidates based on computational strategies.

1

135 A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2. **2021**, 1, 117-138

134 The impact of COVID-19 on chronic therapies: the Pescara (ASL) local health authority experience in Italy. **2021**, 1-6

1

133 Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update. **2020**, 9, 322

132 Hydroxychloroquine in dermatology and beyond: Recent update. **2020**, 11, 453

10

131 Treatment of critically ill COVID-19 patients: Practical guidelines. **2021**, 72, 49-64

130 Recent Advances on Drugs and Vaccines for COVID-19. **2021**, 58, 469580211055630

1

129 Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. **2021**, 319, 01035

128 Anthranilamides with quinoline and Barboline scaffolds: design, synthesis, and biological activity.. **2022**, 1

0

127 In silico evidence of beauvericin antiviral activity against SARS-CoV-2.. **2021**, 141, 105171

4

126 A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.. **2021**, 146, 112550

4

125 Zinc ionophores: chemistry and biological applications.. **2021**, 228, 111691

1


124 Synthesis, Characterization, Antioxidant, Antileishmanial, Anticancer, DNA and Theoretical SARS-CoV-2 Interaction Studies of Copper(II) Carboxylate Complexes.. **2021**, 132308

2

123	Is there a place for anti-inflammatory therapy in COVID-19?. 2020 , 12, 7076-7080	
122	Treatment and prognosis of COVID-19: Current scenario and prospects (Review). 2020 , 20, 1-1	9
121	Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro.. 2022 , 27,	0
120	Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective.. 2022 , 27,	4
119	Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection.	0
118	Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS-CoV-2 main protease and 3C-like protease for COVID-19 treatment.. 2022 ,	3
117	Strategies for drug repurposing against coronavirus targets.. 2022 , 3, 100072	1
116	Electrocatalytic Determination of Hydroxychloroquine Using Sodium Dodecyl Sulphate Modified Carbon Nanotube Paste Electrode.. 2022 , 1-9	0
115	Excavating phytochemicals from plants possessing antiviral activities for identifying SARS-CoV hemagglutinin-esterase inhibitors by diligent computational workflow.. 2022 , 1-16	0
114	Clinical and radiographic course of a patient with late-onset, rapidly progressive, MRI-negative myelitis after COVID-19 illness.. 2022 , 214, 107152	
113	Nanotechnology Toolkit for Combating COVID-19 and Beyond.. 2022 , 8, e202100505	1
112	The QTc interval and treatment outcome of inpatients with COVID-19. 2021 , 18, 63-73	
111	Lesson learned from coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) and socioeconomic impact of (SARS-CoV-2) pandemic. 2022 , 19-36	
110	COVID-19: A systematic review and update on prevention, diagnosis, and treatment.. 2022 , 3, e115	2
109	Synthesis, Cytotoxicity, Molecular Docking, Molecular Simulation and ADME Properties of Cinnamoylated Chloroquine Hybrid Analogues as Corona Virus Protease Inhibitors. 2022 , 38, 163-171	
108	A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.. 2022 , 16, 685-715	2
107	Exploring the potentials of phytochemicals for targeting coronavirus.. 2022 , 12,	
106	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities.. 2022 , 101186	1

105	Effects of Imfluna, an Iranian traditional polyherbal medicine, on COVID-19 symptoms: A randomized, double-blind and placebo-controlled clinical trial. 2022 , 21, 51-66		0
104	Functional food: complementary to fight against COVID-19.. 2022 , 11, 33		0
103	Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.. 2022 , 16, 102451		5
102	Synthesis of new series of quinoline derivatives with insecticidal effects on larval vectors of malaria and dengue diseases.. 2022 , 12, 4765		4
101	Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation.. 2022 ,		
100	One-Pot Synthesis and Molecular Modeling Studies of New Bioactive Spiro-Oxindoles Based on Uracil Derivatives as SARS-CoV-2 Inhibitors Targeting RNA Polymerase and Spike Glycoprotein.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	6
99	Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 .. 2022 , 13, 721103		1
98	Potential impact of serpin peptidase inhibitor clade (A) member 4 SERPINA4 (rs2093266) and SERPINA5 (rs1955656) genetic variants on COVID-19 induced acute kidney injury.. 2022 , 101023		
97	Selenium in the Prevention of SARS-CoV-2 and Other Viruses.. 2022 , 1		3
96	Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	1
95	Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. 2022 ,		
94	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.. 2022 , 11,		0
93	Features, modulation and analysis of glycosylation patterns of therapeutic recombinant immunoglobulin A.. 2022 , 1-23		1
92	Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.. 2022 , 71, 126954		1
91	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. 2022 , 179, 106201		3
90	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. 2022 ,		0
89	Acute respiratory syndrome-2 (SARS-CoV-2): A solution of hydrogen peroxide and sodium bicarbonate as an expectorant for recanalization of the respiratory tract and blood oxygenation in respiratory obstruction (review). 2021 , 19, 383-393		
88	Spatiotemporal spread characteristics and influencing factors of COVID-19 cases: Based on big data of population migration in China.		1

87	Molecular Docking Approach of Natural Compound from Herbal Medicine in Java against Severe Acute Respiratory Syndrome Coronavirus-2 Receptor. 2021 , 9, 1181-1186	2
86	Allosteric Modulation of Small Molecule Drugs on ACE2 Conformational Change upon Binding to SARS-CoV-2 Spike Protein. 2021 ,	1
85	A Systematic Review on the Therapeutic Relevance of Hydroxychloroquine/Chloroquine in the Management of COVID-19. 2021 , 46, 380-388	0
84	Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine.. 2022 , 290, 119500	3
83	COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities.. 2022 , 27, 101612	2
82	Data_Sheet_1.docx. 2020 ,	
81	Data_Sheet_2.docx. 2020 ,	
80	Image_1.tif. 2020 ,	
79	Image_2.TIF. 2020 ,	
78	Image_3.TIF. 2020 ,	
77	Image_4.TIF. 2020 ,	
76	Table_1.doc. 2020 ,	
75	Data_Sheet_1.pdf. 2020 ,	
74	Image_1.TIF. 2020 ,	
73	Image_2.TIF. 2020 ,	
72	Image_3.TIF. 2020 ,	
71	DataSheet_1.pdf. 2020 ,	
70	DataSheet_2.pdf. 2020 ,	

69	Image_1.pdf. 2020 ,		
68	Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial. <i>Medical Gas Research</i> , 2022 , 12, 55-59	2.2	0
67	Higher coronavirus disease-19 mortality linked to comorbidities: A comparison between low-middle income and high-income countries.. <i>Journal of Education and Health Promotion</i> , 2021 , 10, 377	1.4	0
66	Efficacy of oseltamivir in the treatment of patients infected with Covid-19.. <i>Annals of Medicine and Surgery</i> , 2022 , 77, 103679	2	1
65	Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. <i>World Journal of Experimental Medicine</i> , 2022 , 12, 44-52	0.4	0
64	Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability. <i>Expert Review of Anti-Infective Therapy</i> ,	5.5	
63	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
62	Perspective Chapter: Repurposing Natural Products to Target COVID-19: Molecular Targets and New Avenues for Drug Discovery.		
61	Integrative Medicine in the Treatment of COVID-19: The Indian Way. <i>Current Traditional Medicine</i> , 2022 , 08,	0.8	
60	COVID-19: Origin, epidemiology, virology, pathogenesis, and treatment. 2022 , 1-17		
59	Therapeutic options in coronavirus treatment. 2022 , 101-135		
58	Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019. 2022 , 153-168		0
57	COVID-19 outbreak. 2022 , 17-36		
56	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 603-617	2.9	0
55	 COVID-19. <i>Grail of Science</i> , 2022 , 603-607		
54	Awareness, Knowledge, and Perceptions of COVID-19 Precautions Among Employees of Al-Imam Abdulrahman Al Faisal Hospital in Riyadh, KSA. <i>Cureus</i> , 2022 ,	1.2	
53	Environmentally Benign Approaches towards the Synthesis of Quinolines. <i>ChemistrySelect</i> , 2022 , 7,	1.8	0
52	Computing Basis and Dimension of Chloroquine and Hydroxychloroquine by Using Chemical Graph Theory. <i>Polycyclic Aromatic Compounds</i> , 1-17	1.3	1

51	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , 2022 , 15, 739	5.2	2
50	Molecular docking and molecular dynamic simulation approaches for drug development and repurposing of drugs for severe acute respiratory syndrome-Coronavirus-2. 2022 , 207-246		0
49	The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs. <i>Microorganisms</i> , 2022 , 10, 1294	4.9	
48	Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). <i>Journal of Heterocyclic Chemistry</i> ,	1.9	0
47	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022 , 11, 269-297	3	0
46	An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.		0
45	Exploring the Potential of Chemical Inhibitors for Targeting Post-translational Glycosylation of Coronavirus (SARS-CoV-2). 2022 , 7, 27038-27051		1
44	A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic.		1
43	Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. 2022 , 17, e0272034		0
42	Secondary Metabolites Produced by Trees and Fungi: Achievements So Far and Challenges Remaining. 2022 , 13, 1338		0
41	One-Pot Synthesis of Novel Functionalized Fused Pyridine Derivatives via Consecutive Pyrrolidine Ring-Closure/Ring-Opening/Formal Aza-Diels-Alder Reactions.		
40	A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance. 2022 , 36,		
39	Are herbal-peptides effective as adjunctive therapy in Coronavirus disease COVID-19?. 2022 , 14,		
38	Construction of ANbO ₃ (A= Na, K)/f-carbon nanofiber composite: Rapid and real-time electrochemical detection of hydroxychloroquine in environmental samples. 2022 , 215, 114232		1
37	Computational Docking Study of Calanolides as Potential Inhibitors of SARS-CoV-2 Main Protease. 2022 , 10, 48-59		0
36	Application of nanotechnology in drug development and delivery for SARS-CoV-2 treatment. 2022 , 249-260		0
35	Precision Medicine in Infectious Disease. 2022 , 221-257		0
34	Plant-based nanoformulations for human viral diseases. 2022 , 333-355		0

- 33 Withania somnifera (L.) Dunal (Ashwagandha) for the possible therapeutics and clinical management of SARS-CoV-2 infection: Plant-based drug discovery and targeted therapy. 12, 0
- 32 Long COVID-19 and the heart: is cardiac mitochondria the missing link?. 0
- 31 Correlation between Type I Interferon Associated Factors and COVID-19 Severity. **2022**, 23, 10968 0
- 30 Revolutionary Solutions for 'Comprehensive Assessment of' COVID-19 Pandemic. **2023**, 183-195 0
- 29 Computational Modeling of Protease Inhibitors for the Development of Drugs Against Coronaviruses. **2021**, 473-493 0
- 28 Eco design for Ag-based solutions against SARS-CoV-2 and E. coli. 2
- 27 Recommended tactics for mass vaccination of healthy individuals and COVID-19 convalescents. **2022**, 4-12 0
- 26 Syntheses and Structural Characterization of Divalent Metal Complexes (Co, Ni, Pd and Zn) of Sterically Hindered Thiourea Ligand and A Theoretical Insight of their Interaction with SARS-CoV-2 Enzyme. **2022**, 134442 0
- 25 Lung Ultrasound as a Triage Method in Primary Care for Patients with Suspected SARS-CoV-2 Pneumonia. **2022**, 11, 6420 0
- 24 COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12 0
- 23 Viral Infection and Antiviral Treatments in Ocular Pathologies. **2022**, 10, 2224 0
- 22 Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. **2022**, 20, 1
- 21 An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus. **2023**, 152, 106433 0
- 20 An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. 13, 1
- 19 Azole derivatives inhibit the binding of the RBD domain of SARS-Cov-2 against host ACE2 in in vitro assays. **2022**, 9, 58-63 0
- 18 Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata. 13, 0
- 17 Evolving pharmaceutical therapies for confronting COVID-19: An overview. **2022**, 0
- 16 Investigation on Phyto-active Constituent of Clerodendrum paniculatum as Therapeutic Agent against Viral Diseases. **2023**, 8, 0

- 15 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 14 Quinoline analogue as a potential inhibitor of SARS-CoV-2 main protease: ADMET prediction, molecular docking and dynamics simulation analysis. **2023**, 14, 30-38 ○
- 13 Coronavirus pathogenesis in mice explains the SARS-CoV-2 multi-organ spread by red blood cells hitch-hiking. ○
- 12 Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. **2023**, 152, 1-21 ○
- 11 Fe(VI) activation system mediated by a solar-driven TiO₂ nanotubes electrode for CLQ degradation: Performances, mechanisms and pathways. **2023**, 452, 131274 ○
- 10 A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. **2023**, 11, 332 ○
- 9 Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges. **2023**, 451-478 ○
- 8 COVID -19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats. **2023**, 11, ○
- 7 Analytical approaches for determination of COVID-19 candidate drugs in human biological matrices. **2023**, 160, 116964 ○
- 6 Density Functional Studies of Hydroxychloroquine and Chloroquine Reveals Higher Reactivity and Potential of Anionic Form of Hydroxychloroquine. **2023**, 407, ○
- 5 In silico application of data science, genomics, and bioinformatics in screening drug candidates against COVID-19. **2023**, 107-128 ○
- 4 Novel ortho- phenylenediamine derivatives as spike glycoprotein coronavirus 2019-nCoV inhibitors: molecular docking study. **2020**, 7, 70-74 ○
- 3 Phytomolecules and Novel Drug Delivery Approach for COVID-19. **2023**, 375-405 ○
- 2 COVID-19: An evidence-based and disaster response methodology. **2023**, 0 ○
- 1 New targets for old drugs. **2023**, 315-349 ○